SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics announced positive 12-week induction data from Part…

Spyre Therapeutics, Inc. · PRESS-RELEASE filed Apr 13, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 13, 2026 at 07:00 ET

Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 achieved a statistically significant 9.2-point reduction in RHI score (p<0.0001) with strong secondary outcomes and a favorable safety profile. Enrollment has closed for Part A and moved to Part B, which includes monotherapy and combination cohorts, with data readouts expected through 2026–2027.

  • SPY001 met primary endpoint with 9.2-point reduction in RHI score (p<0.0001) at Week 12 in Phase 2 SKYLINE trial Part A.
  • Secondary endpoints: 40% clinical remission rate and 51% endoscopic improvement rate.
  • SPY001 was well tolerated with no drug-related serious adverse events; most common AE was back pain (n=2).
  • Part B of the SKYLINE trial is now enrolling, including combination cohorts with SPY002 and SPY003.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access